These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16635282)

  • 1. Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
    Cassinello J; Alvarez JV; López MJ; Pujol E; Colmenarejo A; Segovia F; Marcos F; Filipovich E; Arcediano A; Castro IG
    Clin Colorectal Cancer; 2006 Mar; 5(6):429-35. PubMed ID: 16635282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
    Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
    Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
    Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.
    Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D
    Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
    Pfeiffer P; Sørbye H; Ehrsson H; Fokstuen T; Mortensen JP; Baltesgard L; Tveit KM; Øgreid D; Starkhammar H; Wallin I; Qvortrup C; Glimelius B
    Ann Oncol; 2006 Feb; 17(2):252-8. PubMed ID: 16291583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer.
    Bajetta E; Verzoni E; Ferrario E; Dotti K; Gevorgyan A; Celio L
    Tumori; 2009; 95(1):43-7. PubMed ID: 19366055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
    Zeuli M; Di Costanzo E; Sdrobolini A; Gasperoni S; Paoloni FP; Carpi A; Moscetti L; Cherubini R; Cognetti F; ;
    Ann Oncol; 2001 Dec; 12(12):1737-41. PubMed ID: 11843252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
    Meyerhardt JA; Zhu AX; Enzinger PC; Ryan DP; Clark JW; Kulke MH; Earle CC; Vincitore M; Michelini A; Sheehan S; Fuchs CS
    J Clin Oncol; 2006 Apr; 24(12):1892-7. PubMed ID: 16622264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
    Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
    Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
    Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
    Di Bartolomeo M; Ciarlo A; Bertolini A; Barni S; Verusio C; Aitini E; Pietrantonio F; Iacovelli R; Dotti KF; Maggi C; Perrone F; Bajetta E
    Eur J Cancer; 2015 Mar; 51(4):473-481. PubMed ID: 25637137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
    Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
    Rosati G; Cordio S; Bordonaro R; Caputo G; Novello G; Reggiardo G; Manzione L
    Ann Oncol; 2010 Apr; 21(4):781-786. PubMed ID: 19713248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
    Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G
    Oncology; 2005; 69(1):27-34. PubMed ID: 16088232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
    Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
    Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
    Shin SJ; Ahn JB; Park KS; Lee YJ; Hong YS; Kim TW; Kim HR; Rha SY; Roh JK; Kim DH; Kim C; Chung HC
    Invest New Drugs; 2012 Apr; 30(2):672-80. PubMed ID: 21188464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.